Trial Profile
A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Mar 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Advanced breast cancer; Anal cancer; Bladder cancer; Cervical cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Vulvovaginal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Study 10
- Sponsors AstraZeneca; MedImmune
- 13 Feb 2021 Results of retrospective post hoc analysis from two studies (study 1108 and study 10 ) presented at the 2021 Genitourinary Cancers Symposium
- 05 Mar 2020 Status changed from active, no longer recruiting to completed.
- 27 Aug 2019 Planned End Date changed from 9 Sep 2019 to 29 Jan 2020.